At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 231 enrolled
Drug / intervention
Efimosfermin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Blinded, Placebo-controlled Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With a Single Arm Open-label Extension
In Brief
A Phase 2 clinical trial evaluating Efimosfermin and Placebo for Nonalcoholic Steatohepatitis (NASH). Completed, enrolled 231 participants across 48 sites.
Detailed Summary
This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension. It includes Parts A, B, C and D.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonalcoholic Steatohepatitis (NASH)
CountriesUnited States
CollaboratorsGSK Research and Development Limited
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartSep 2021
Primary CompletionOct 2025
TodayJul 2026
First PostedMay 10, 2021
Enrollment StartSep 30, 2021
Primary CompletionOct 27, 2025
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 5.1 years ago
Interventions
Efimosfermindrug
Efimosfermin will be administered by subcutaneous injection
Placebodrug
Placebo will be administered by subcutaneous injection